Vascular-disrupting agents in oncology

Bibliography

• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus Interferon Alfa in metastatic renal cellcarcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Elias AD, Kelbick NT, Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;10:3124-9
   Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14(11):1131-8
   PubMed Web of Science ®Google Scholar
• Nathan PD, Judson I, Padhani A, A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):abstract 3550
   Google Scholar
• Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-31
   PubMed Web of Science ®Google Scholar
• Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045-50
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
   PubMed Web of Science ®Google Scholar
• Rustin GJS, Galbraith SM, Anderson H, Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Radema SA, Witteveen EO, Phase I clinical evaluation of weekly administration of the novel vascular- targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8
   PubMed Web of Science ®Google Scholar
• Pries AR, Reglin B, Secomb TW. Modeling of angioadaptation: insights for vascular development. Int J Dev Biol 2011;55:399-405
   PubMed Web of Science ®Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer 2005;5:423-35
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Maione P, Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009;14:612-20
   PubMed Web of Science ®Google Scholar
• Cooney MM, Heckeren W, Bhakta S. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat Clin Pract Oncology 2006;3:682-92
   PubMedGoogle Scholar
• Sander A, Schiller J, Gray R, Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12
   PubMed Web of Science ®Google Scholar
• Nathan PD, Judson I, Padhani A, A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):abstract 3550
   Google Scholar
• Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-31
   PubMed Web of Science ®Google Scholar
• Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045-50
   PubMed Web of Science ®Google Scholar
• Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. J Cancer Res Clin Oncol 2011;137:1619-27
   PubMed Web of Science ®Google Scholar
• Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy. Int J Cancer 2002;99:1-6
   PubMed Web of Science ®Google Scholar
• Siim BG, Lee AE, Shalal-Zwain S, Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
   PubMed Web of Science ®Google Scholar
• Nathan PD, Judson I, Padhani A, A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):abstract 3550
   Google Scholar
• A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Naïve Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00653939
   Google Scholar
• McKeage MJ, Jameson MB. AS1404-201 Study Group Investigators Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) – retrospective analysis of pooled data. J Thorac Dis 2010;2:199-204
   Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Reck M, Jameson MB, Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-7
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Scagliotti G, von Pawel J, Reck M, Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV nonsmall cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, doubleblind, placebo-controlled, ESCAPE (evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial. Late breaking abstract presented at 1st European Lung Cancer Conference; 2008
   Google Scholar
• Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995;36:143-8
   PubMed Web of Science ®Google Scholar
• Corbett TH, Bissery MC, Wozniak A, Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 1986;4:207-20
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard J-Y, Nakagawa K, Randomized Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Fong P, Jeffery M, 5,6-dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a Phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
   PubMed Web of Science ®Google Scholar
• Gabra H; AS1404-202 Study Group Investigators. Phase II study of vadimezan combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006;24(Suppl):5032
   Google Scholar
• Pili R, Rosenthal M. AS1404-203 study group investigators. Addition of vadimezan (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol 2008;26(Suppl):5007
   Google Scholar
• McKeage MJ, Jameson MB. Comparison of safety and efficacy between squaomous and non-squamous non-small cell lung cancer patients in a Phase II study of vadimezan (ASA404). J Clin Oncol 2008;26(Suppl 15):441s
   Google Scholar
• McKeage MJ, Reck M, Jameson MB, Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/vadimezan) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65(2):192-7
   PubMed Web of Science ®Google Scholar
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00662597
   Google Scholar
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00738387
   Google Scholar
• Lara P, Douillard J, Nakagawa K, Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Boerner SA. Clinical Development of vascular disrupting agents: what lessions can we learn from ASA404? J Clin Oncol 2011;29:2952-5
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumor vascular targeting agents. Int J of Exp Pathol 2002;83:21-38
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing. Anticancer Drugs 1993;4:3-17
   Web of Science ®Google Scholar
• Vincent L, Kermani P, Young LM, Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelis-cadherin signaling. J Clin Invest 2005;115:2992-3006
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, Combretastatin A4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34
   PubMed Web of Science ®Google Scholar
• Kolomeichuk SN, Terrano DT, Lyle CS, Distinct signaling pathways of microtubule inhibitors – vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J 2008;275:1889-99
   PubMed Web of Science ®Google Scholar
• Yeung S-CJ, She M, Yang H, Combination chemotherapy including combretastatin A4 Phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 2007;92:2902-9
   PubMed Web of Science ®Google Scholar
• Xu G, Pan J, Martin C, Yeung S-CJ. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. 2001;86(4):1769-77
   Google Scholar
• Cooney MM, Radivoyevitch T, Dowlati A, Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose Phase I study in patients with advanced cancer. Clin Cancer Res 2004;10(1 Pt 1):96-100
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Galbraith SM, Anderson H, Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21(15):2815-22
   PubMed Web of Science ®Google Scholar
• Bilenker JH, Flaherty KT, Rosen M, Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin. Clin Cancer Res 2005;11:1527-33
   PubMed Web of Science ®Google Scholar
• Dziba JM, Marcinek R, Venkataraman G, Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002;12(12):1063-70
   PubMed Web of Science ®Google Scholar
• Sosa JA, Elisei R, Jarzab B, A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin and paclitaxel in anaplastic thyroid cancer: final survival analysis for FACT trial. J Clin Oncol 2011;29(Suppl):abstract 5502
   Google Scholar
• Zweifel M, Jayson GC, Reed NS, Phase II trial of combretastatin A-4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2036-41
   PubMed Web of Science ®Google Scholar
• Nathan PD, Judson I, Padhani A, A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):3550
   Google Scholar
• Garon EB, Kabbinavar FF, Neidhart JA, A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin, paclitaxel and bevacizumab in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 2011;29(Suppl):abstract 7559
   Google Scholar
• Bevacizumab with or without fosbretabulin tromethamine in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01305213
   Google Scholar
• Nicholson B, Lloyd GK, Miller BR, NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17:25-31
   PubMed Web of Science ®Google Scholar
• Mita M, Spear MA, Yee LK, Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 2010;16(23):5892-9
   PubMed Web of Science ®Google Scholar
• Lloyd GK, Nicholson B, Neuteboom STC, NPI-2358: a new vascular/tubulin modifying agent greatly potentiates standard chemotherapy in xenograft models. EORTC-NCI-AACR Molecular Targets and Therapeutics Meeting; Boston, MA; 2003
   Google Scholar
• Neuteboom STC, Medina E, Palladino MA, NPI-2358, A novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV52 [abstract 141]. Eur J Cancer 2008;6(Suppl):40-0
   Google Scholar
• Millward M, Mainwaring P, Mita A, Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs 2012;30:1065-73
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Prospective randomized trial of docetaxel versus best supportive care in patients with non–small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22158997
   PubMed Web of Science ®Google Scholar
• Mita AC, Heist RS, Aren O, Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC) [abstract 7592]. J Clin Oncol 2010;28(Suppl)):15s
   PubMedGoogle Scholar
• Sessa C, Lorusso P, Tolcher AW, A pharmacokinetic and DCE-MRI-dynamic phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Amer Assoc Cancer Res 2005;46
   Google Scholar
• Chebil M, Soria J, Chami L, Interest of DCE-US with quantification to demonstrate the VDA effect on vascularization in patients with advanced solid tumors treated with AVE8062. J Clin Oncol 2009;27(Suppl):e14522
   Google Scholar
• A study of AVE8062 in advanced-stage soft tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00699517
   Google Scholar
• AVE8062 in association with doublet chemotherapy cisplatin and docetaxel in advanced solid tumor. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00719524
   Google Scholar
• Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18(10):1541-8
   PubMed Web of Science ®Google Scholar
• Ong M, del Conte G, Bahleda R, A phase I study of ombrabulin combined with bevacizumab in patients with advanced solid tumors – preliminary results [abstract L6.5]. Anals Oncology 2012;23(Suppl):i15-25
   Google Scholar
• Kurzrock R, Akerley W, Hong D, Two Phase 1 studies of MPC-6827, a novel vascular disrupting agents (VDA), in patients with advanced solid tumors and CNS metastasis. J Clin Oncol 2007;25(20 Suppl):3604
   Google Scholar
• Tsimberidou AM, Akerley W, Schabel MC, Phase I Clinical Trial of MPC-6827 (Azixa), A Microtubule Destabilizing Agent, in Patients with Advanced Cancer. Mol Cancer Ther 2010;9:3410-19
   PubMed Web of Science ®Google Scholar
• Phase 2 study of Azixa (MPC-6827) for the treatment of glioblastoma after bevacizumab failure. Society for Neuro-Oncology Scientific Meeting; 2010
   Google Scholar
• Zhu J-J, Recht LD, Colman H, Phase II study using the response assessment in neuro-oncology (RANO) criteria to evaluate the efficacy of verubulin with radiation therapy and temozolomide in subjects newly diagnosed with glioblastoma multiforme: part a safety and tolerability results [abstract OT-08]. Neuro-Oncology 2011;13:iii85-91
   Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl):abstract LBA5002
   Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-68
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol 2012;24(1):8-13
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Flynn PJ, Kozloff M, Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 2012;48:1126-32
   PubMed Web of Science ®Google Scholar
• Clemenson C, Jouannot E, Merino-Trigo A, The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Scartozzi M, Galizia E, Chiorrini S, Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20(2):227-30
   PubMed Web of Science ®Google Scholar